INTRODUCTION: Catheter-associated infection of cerebrospinal fluid (CSF) is a potentially life-threatening complication of external ventricular drainage (EVD). The purpose of this pilot study was to address the efficacy of silver-impregnated EVD catheters in neurological and neurosurgical patients requiring external CSF drainage due to acute occlusive hydrocephalus. METHODS: Nineteen consecutive patients were enrolled in the treatment arm of the study and data were prospectively recorded for these patients. The control group consisted of 20 patients for whom data were retrospectively assessed. CSF samples were drawn at least three times a week and routine bacterial cultures and CSF analyses were done according to standard protocols. The primary endpoint of the study was the occurrence of catheter-associated ventriculitis (CAV) proven by positive CSF culture. Secondary endpoints were bacterial colonization of the catheter tip and CSF pleocytosis. RESULTS: In 20 control patients, 5 CAVs were microbiologically diagnosed. In contrast, no positive CSF cultures were found in the treatment group. This difference was statistically significant (P < 0.05). All CAVs occurred later than day 10 after catheter placement. Colonization of the catheter tip was found in 6 patients in the control group and in 5 patients in the treatment group (not significant). CONCLUSIONS: This pilot study indicates that EVD catheters impregnated with silver nanoparticles might be a new option for preventing CAV in neurocritical care patients, and therefore evaluation in a large prospective randomized study is warranted.
INTRODUCTION: Catheter-associated infection of cerebrospinal fluid (CSF) is a potentially life-threatening complication of external ventricular drainage (EVD). The purpose of this pilot study was to address the efficacy of silver-impregnated EVD catheters in neurological and neurosurgical patients requiring external CSF drainage due to acute occlusive hydrocephalus. METHODS: Nineteen consecutive patients were enrolled in the treatment arm of the study and data were prospectively recorded for these patients. The control group consisted of 20 patients for whom data were retrospectively assessed. CSF samples were drawn at least three times a week and routine bacterial cultures and CSF analyses were done according to standard protocols. The primary endpoint of the study was the occurrence of catheter-associated ventriculitis (CAV) proven by positive CSF culture. Secondary endpoints were bacterial colonization of the catheter tip and CSF pleocytosis. RESULTS: In 20 control patients, 5 CAVs were microbiologically diagnosed. In contrast, no positive CSF cultures were found in the treatment group. This difference was statistically significant (P < 0.05). All CAVs occurred later than day 10 after catheter placement. Colonization of the catheter tip was found in 6 patients in the control group and in 5 patients in the treatment group (not significant). CONCLUSIONS: This pilot study indicates that EVD catheters impregnated with silver nanoparticles might be a new option for preventing CAV in neurocritical care patients, and therefore evaluation in a large prospective randomized study is warranted.
Authors: Klaus Galiano; Claudia Pleifer; Klaus Engelhardt; Gregor Brössner; Peter Lackner; Christian Huck; Cornelia Lass-Flörl; Alois Obwegeser Journal: Neurol Res Date: 2007-08-31 Impact factor: 2.448
Authors: Pierre Kalfon; Cyrille de Vaumas; Désiré Samba; Eric Boulet; Jean-Yves Lefrant; Daniel Eyraud; Thierry Lherm; François Santoli; Walid Naija; Bruno Riou Journal: Crit Care Med Date: 2007-04 Impact factor: 7.598
Authors: Herbert I Fried; Barnett R Nathan; A Shaun Rowe; Joseph M Zabramski; Norberto Andaluz; Adarsh Bhimraj; Mary McKenna Guanci; David B Seder; Jeffrey M Singh Journal: Neurocrit Care Date: 2016-02 Impact factor: 3.210
Authors: P Ramírez; M Gordón; A Soriano; S Gil-Perotin; V Marti; E M Gonzalez-Barbera; M T Sanchez-Aguilar; J A Simal; J Bonastre Journal: Eur J Clin Microbiol Infect Dis Date: 2013-05-25 Impact factor: 3.267
Authors: Michael D Jenkinson; Carrol Gamble; John C Hartley; Helen Hickey; Dyfrig Hughes; Michaela Blundell; Michael J Griffiths; Tom Solomon; Conor L Mallucci Journal: Trials Date: 2014-01-03 Impact factor: 2.279
Authors: Conor L Mallucci; Michael D Jenkinson; Elizabeth J Conroy; John C Hartley; Michaela Brown; Tracy Moitt; Joanne Dalton; Tom Kearns; Michael J Griffiths; Giovanna Culeddu; Tom Solomon; Dyfrig Hughes; Carrol Gamble Journal: Health Technol Assess Date: 2020-03 Impact factor: 4.014